Literature DB >> 24981892

Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy.

Vijaya B Joshi1, Andrea Adamcakova-Dodd, Xuefang Jing, Amaraporn Wongrakpanich, Katherine N Gibson-Corley, Peter S Thorne, Aliasger K Salem.   

Abstract

Poly(lactic-co-glycolic acid) (PLGA) particles carrying antigen and adjuvant is a promising vaccine system which has been shown to stimulate systemic antigen-specific immune responses. In this study, we investigated the relationship of (i) the sizes of PLGA particle and (ii) the presence of cytosine-phosphate-guanine motifs (CpG), with the extent and type of immune response stimulated against Dermatophagoides pteronyssinus-2 (Der p2) antigen. Different sizes of PLGA particles encapsulating CpG were prepared using a double emulsion solvent evaporation method. Mice were vaccinated with Der p2 and different sizes of empty or CpG-loaded PLGA particles. Vaccinated mice were exposed to daily intranasal instillation of Der p2 for 10 days followed by euthanization to estimate leukocyte accumulation in bronchoalveolar lavage (BAL) fluids, antibody profiles, and airway hyperresponsiveness. PLGA particles showed a size-dependent decrease in the proportion of eosinophils found in BAL fluids. Mice vaccinated with the Der p2 coated on 9-μm-sized empty PLGA particles showed increased levels of IgE and IgG1 antibodies as well as increased airway hyperresponsiveness. All sizes of PLGA particles encapsulating CpG prevented airway hyperresponsiveness after Der p2 exposures. Inflammatory responses to Der p2 exposure were significantly reduced when smaller PLGA particles were used for vaccination. In addition, encapsulating CpG in PLGA particles increased IgG2a secretion. This study shows that the size of PLGA particles used for vaccination plays a major role in the prevention of house dust mite-induced allergy and that incorporation of CpG into the PLGA particles preferentially develops a Th1-type immune response.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24981892      PMCID: PMC4147059          DOI: 10.1208/s12248-014-9624-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  52 in total

Review 1.  Immunologic basis of antigen-induced airway hyperresponsiveness.

Authors:  M Wills-Karp
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  House dust mite allergen in US beds: results from the First National Survey of Lead and Allergens in Housing.

Authors:  Samuel J Arbes; Richard D Cohn; Ming Yin; Michael L Muilenberg; Harriet A Burge; Warren Friedman; Darryl C Zeldin
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

Review 3.  Dust mite allergens: ecology and distribution.

Authors:  Larry G Arlian; Marjorie S Morgan; Jacqueline S Neal
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

4.  Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling.

Authors:  Jill R Johnson; Ryan E Wiley; Ramzi Fattouh; Filip K Swirski; Beata U Gajewska; Anthony J Coyle; José-Carlos Gutierrez-Ramos; Russ Ellis; Mark D Inman; Manel Jordana
Journal:  Am J Respir Crit Care Med       Date:  2003-11-03       Impact factor: 21.405

5.  Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation.

Authors:  P S Thorne; P B McCray; T S Howe; M A O'Neill
Journal:  Am J Respir Cell Mol Biol       Date:  1999-06       Impact factor: 6.914

6.  Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production.

Authors:  Li Kiang Tan; Chiung-Hui Huang; I-Chun Kuo; Lee Mei Liew; Kaw Yan Chua
Journal:  Vaccine       Date:  2006-05-11       Impact factor: 3.641

7.  Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

Authors:  F Estelle R Simons; Yasufumi Shikishima; Gary Van Nest; Joseph J Eiden; Kent T HayGlass
Journal:  J Allergy Clin Immunol       Date:  2004-06       Impact factor: 10.793

8.  Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy.

Authors:  Pinya Pulsawat; Patrawadee Pitakpolrat; Eakachai Prompetchara; Theerayuth Kaewamatawong; Navapon Techakriengkrai; Sunee Sirivichayakul; Supranee Buranapraditkun; Drew Hannaman; Kiat Ruxrungtham; Alain Jacquet
Journal:  Immunol Lett       Date:  2013-02-08       Impact factor: 3.685

9.  Possible induction of food allergy during mite immunotherapy.

Authors:  R van Ree; L Antonicelli; J H Akkerdaas; M S Garritani; R C Aalberse; F Bonifazi
Journal:  Allergy       Date:  1996-02       Impact factor: 13.146

10.  Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model.

Authors:  I Schöll; A Weissenböck; E Förster-Waldl; E Untersmayr; F Walter; M Willheim; G Boltz-Nitulescu; O Scheiner; F Gabor; E Jensen-Jarolim
Journal:  Clin Exp Allergy       Date:  2004-02       Impact factor: 5.018

View more
  18 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.

Authors:  Sean M Geary; Qiaohong Hu; Vijaya B Joshi; Ned B Bowden; Aliasger K Salem
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

3.  Nanoparticles in vaccine delivery.

Authors:  Aliasger K Salem
Journal:  AAPS J       Date:  2015-01-23       Impact factor: 4.009

4.  Assessing the effect of engineered nanomaterials on the environment and human health.

Authors:  Sean M Geary; Angie S Morris; Aliasger K Salem
Journal:  J Allergy Clin Immunol       Date:  2016-06-27       Impact factor: 10.793

5.  How will nanotechnology lead to better control of asthma?

Authors:  Bumhee Yang; Hayoung Choi; Sang-Heon Kim; Ho Joo Yoon; Hyun Lee
Journal:  Ann Transl Med       Date:  2019-10

Review 6.  Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma.

Authors:  Brittany E Givens; Sean M Geary; Aliasger K Salem
Journal:  Immunotherapy       Date:  2018-03-23       Impact factor: 4.196

Review 7.  Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.

Authors:  Brittany E Givens; Youssef W Naguib; Sean M Geary; Eric J Devor; Aliasger K Salem
Journal:  AAPS J       Date:  2018-10-10       Impact factor: 4.009

8.  A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects.

Authors:  Sheetal R D'Mello; Satheesh Elangovan; Liu Hong; Ryan D Ross; D Rick Sumner; Aliasger K Salem
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.829

9.  Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.

Authors:  Nobutaka Hanagata; Xianglan Li; Min-Hua Chen; Jie Li; Shinya Hattori
Journal:  Int J Nanomedicine       Date:  2017-12-20

10.  Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice.

Authors:  Marie Ballester; Laura Jeanbart; Alexandre de Titta; Chiara Nembrini; Benjamin J Marsland; Jeffrey A Hubbell; Melody A Swartz
Journal:  Sci Rep       Date:  2015-09-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.